Literature DB >> 26646928

Seven-Tesla MRI and neuroimaging biomarkers for Alzheimer's disease.

Rohaid Ali1, Maged Goubran2, Omar Choudhri1, Michael M Zeineh2.   

Abstract

The goal of this paper was to review the effectiveness of using 7-T MRI to study neuroimaging biomarkers for Alzheimer's disease (AD). The authors reviewed the literature for articles published to date on the use of 7-T MRI to study AD. Thus far, there are 3 neuroimaging biomarkers for AD that have been studied using 7-T MRI in AD tissue: 1) neuroanatomical atrophy; 2) molecular characterization of hypointensities; and 3) microinfarcts. Seven-Tesla MRI has had mixed results when used to study the 3 aforementioned neuroimaging biomarkers for AD. First, in the detection of neuroanatomical atrophy, 7-T MRI has exciting potential. Historically, noninvasive imaging of neuroanatomical atrophy during AD has been limited by suboptimal resolution. However, now there is compelling evidence that the high resolution of 7-T MRI may help overcome this hurdle. Second, in detecting the characterization of hypointensities, 7-T MRI has had varied success. PET scans will most likely continue to lead in the noninvasive imaging of amyloid plaques; however, there is emerging evidence that 7-T MRI can accurately detect iron deposits within activated microglia, which may help shed light on the role of the immune system in AD pathogenesis. Finally, in the detection of microinfarcts, 7-T MRI may also play a promising role, which may help further elucidate the relationship between cerebrovascular health and AD progression.

Entities:  

Keywords:  7-T MRI; AD = Alzheimer’s disease; Alzheimer’s; CA1 = Cornu Ammonis 1; PiB = Pittsburgh compound B; amyloid plaques; biomarkers; hippocampal atrophy

Mesh:

Substances:

Year:  2015        PMID: 26646928     DOI: 10.3171/2015.9.FOCUS15326

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  7 in total

1.  In vivo MRI signatures of hippocampal subfield pathology in intractable epilepsy.

Authors:  Maged Goubran; Boris C Bernhardt; Diego Cantor-Rivera; Jonathan C Lau; Charlotte Blinston; Robert R Hammond; Sandrine de Ribaupierre; Jorge G Burneo; Seyed M Mirsattari; David A Steven; Andrew G Parrent; Andrea Bernasconi; Neda Bernasconi; Terry M Peters; Ali R Khan
Journal:  Hum Brain Mapp       Date:  2015-12-17       Impact factor: 5.038

Review 2.  High-resolution Structural Magnetic Resonance Imaging and Quantitative Susceptibility Mapping.

Authors:  Vivek Yedavalli; Phillip DiGiacomo; Elizabeth Tong; Michael Zeineh
Journal:  Magn Reson Imaging Clin N Am       Date:  2021-02       Impact factor: 2.266

3.  Utility of 7 Tesla MRI for Preoperative Planning of Endoscopic Endonasal Surgery for Pituitary Adenomas.

Authors:  John W Rutland; Bradley N Delman; Rebecca E Feldman; Nadejda Tsankova; Hung-Mo Lin; Francesco Padormo; Raj K Shrivastava; Priti Balchandani
Journal:  J Neurol Surg B Skull Base       Date:  2019-11-21

Review 4.  PET/MR Imaging: New Frontier in Alzheimer's Disease and Other Dementias.

Authors:  Xin Y Zhang; Zhen L Yang; Guang M Lu; Gui F Yang; Long J Zhang
Journal:  Front Mol Neurosci       Date:  2017-11-01       Impact factor: 5.639

5.  Assessment of pathological features in Alzheimer's disease brain tissue with a large field-of-view visible-light optical coherence microscope.

Authors:  Antonia Lichtenegger; Martina Muck; Pablo Eugui; Danielle J Harper; Marco Augustin; Konrad Leskovar; Christoph K Hitzenberger; Adelheid Woehrer; Bernhard Baumann
Journal:  Neurophotonics       Date:  2018-07-24       Impact factor: 3.593

Review 6.  Clinical PET Imaging of Microglial Activation: Implications for Microglial Therapeutics in Alzheimer's Disease.

Authors:  Zhiwei Shen; Xinjie Bao; Renzhi Wang
Journal:  Front Aging Neurosci       Date:  2018-10-08       Impact factor: 5.750

7.  In Vivo Imaging of Microglia With Multiphoton Microscopy.

Authors:  Carmen Hierro-Bujalance; Brian J Bacskai; Monica Garcia-Alloza
Journal:  Front Aging Neurosci       Date:  2018-07-19       Impact factor: 5.750

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.